Clinical Trials Logo
  1. Home
  2. Schizophrenia
  3. NCT00873249
  4. Details
NCT00873249 Clinical Trial

Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

Schizophrenia Clinical Trial

— SMS  

Official title:
Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00873249
Other study ID # NIS-NES-DUM-2007/3
Secondary ID
Status Completed
Phase N/A
First received March 31, 2009
Last updated March 23, 2010
Start date April 2009
Est. completion date March 2010

Study information
Verified date March 2010
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Observational

Clinical Trial Summary

This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.

Recruitment information / eligibility
Status Completed
Enrollment 339
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patients older than 18 years

- With a diagnosis of schizophrenia (DSM-IV TR criteria)

- Stabilized out-patients

- Under oral antipsychotic monotherapy

Exclusion Criteria:

- Administration of a depot antipsychotic drug

- Suicide risk

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Spain Research Site Alicante
Spain Research Site Almeria
Spain Research Site Barcelona
Spain Research Site Berga Barcelona
Spain Research Site Burgos
Spain Research Site Calatayud Zaragoza
Spain Research Site Cordoba
Spain Research Site Granada
Spain Research Site Leon
Spain Research Site Lerida
Spain Research Site Madrid
Spain Research Site Malaga
Spain Research Site Murcia
Spain Research Site Oviedo
Spain Research Site Palma Mallorca
Spain Research Site Pamplona Navarra
Spain Research Site Sabadell Barcelona
Spain Research Site Salamanca
Spain Research Site Santander Cantabria
Spain Research Site Sevilla
Spain Research Site Tarragona
Spain Research Site Toledo
Spain Research Site Valencia
Spain Research Site Valladolid
Spain Research Site Zamora

Sponsors (1)
Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Morisky Green Questionnaire baseline, at months 3 and 6 No
Secondary Clinical Global Impression- Schizophrenia (CGI-SCH) baseline, at months 3 and 6 No
Secondary Register of Adherence to Treatment (RAT) baseline, at months 3 and 6 No
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A